Home › Trial NCT03267888
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Trial IDNCT03267888
- StatusCompleted
- PhasePhase 1/2
- Study typeInterventional
- SponsorEmory University
- Enrollment25
- Start date2018-05-29
- ConditionsISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma · Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.